Ask AI
ProCE Banner Activity

Beyond Resistance: Integrating Next-Generation SERDs Into Community Management of ER-Positive/HER2-Negative Advanced Breast Cancer

Slideset

Downloadable slides on integrating next-generation oral SERDs and other ER-directed therapies into biomarker-driven management of ER-positive/HER2-negative advanced breast cancer, including ESR1 mutation testing, emerging clinical trial data, treatment sequencing, and toxicity management.

Released: May 28, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

Supported by educational grants from Lilly, Rigel Pharmaceuticals, Inc., and Stemline Therapeutics, Inc. 

Lilly

Rigel Pharmaceuticals, Inc.

Stemline Therapeutics, Inc.

Target Audience

This educational activity is intended for medical oncologists, pathologists, nurses, nurse practitioners, pharmacists, physician associates, and other healthcare professionals who care for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Educate patients and colleagues on the mechanisms of action and biologic rationales for using next-generation SERDs in endocrine-resistant ER-positive/HER2-negative ABC

  • Design individualized treatment plans incorporating next-generation SERDs for appropriate patients with ER-positive/HER2-negative ABC based on biomarker testing results, patient factors, clinical data, and expert recommendations

  • Appraise the potential clinical implications of emerging data and ongoing trials evaluating next-generation SERDs on management of patients with ER-positive/HER2-negative ABC

  • Implement interprofessional team processes and workflows to identify actionable ESR1 mutations and support timely intervention in patients with ER-positive/HER2-negative ABC

  • Collaborate with interdisciplinary colleagues to effectively manage treatment-related toxicities and support treatment adherence/persistence to next-generation SERD therapy